Abstract

An antisense oligonucleotides having the ability to decrease the expression level of the huntingtin protein in glioma cells, for their use in sensitizing the cells to an anti-cancer treatment.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/175 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine having the group , N—C(O)—N=N— or , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazonesThioanalogues thereof
• A61K 31/282 - Platinum compounds
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61P 35/00 - Antineoplastic agents

Abstract

In the present invention, inventors report the characterization of BCLA (Brain Cyst Load-associated Antigen), a protein exclusively expressed during the bradyzoite stage of the parasite. In cysts directly purified from the brain of mice, the protein is distributed within and at the surface of the cyst. ELISA antibody capture using a combination of serologically reactive BCLA peptides and a recombinantly expressed c-terminal domain (rBCLA) constitutes an efficient serological marker of latent infection with a high sensitivity that is clearly and exclusively correlated with the presence of cysts in the brain of mice Antibodies directed against BCLA antigen have been detected in human patients with enriched titers in patients qualified as seropositive to Sag1 or tachyzoite related antigens. Further correlation in humans between anti-BCLA IgG synthesis and cysts is brought by significantly stronger recorded titers in pathological panels strongly related to the presence of cyst. Furthermore, newborn infants with a confirmed congenital toxoplasmosis display significantly higher anti-BCLA IgGs at birth when compared to their mother, suggesting a specific in-utero neosynthesis of such IgGs. Thus the invention relates to a new Toxoplasma gondii protein, hereafter referred as BCLA, a new serological marker whose expression is restricted to the latent form of Toxoplasmosis (bradyzoite/cyst). This specific protein and its antigenic fragments can be used to detect autoantibodies in the sera of patient for the diagnosis of the latent form of Toxoplasmosis. The invention also relates to derived antibodies, generated by BCLA immunisation that specifically binds this new protein.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention relates to a nanostructured biomimetic neuromorphic system including a solution comprising inverted micelles (14) in contact with each other so as to form lipid bilayers (13) at contact points, at least part of said contact points comprising at least one ion transporting membrane protein (15) allowing at least one ion transport from an inverted micelle (14) to another in return for a reverse exchange of at least one ion, wherein said solution comprising inverted micelles (14) is a compacted emulsion (10). Such system permits the creation of an ionic gradient that permits to generate a voltage.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• H01M 14/00 - Electrochemical current or voltage generators not provided for in groups Manufacture thereof
• A61B 5/388 - Nerve conduction study, e.g. detecting action potential of peripheral nerves

Abstract

The invention relates to antisense oligonucleotides having the ability to reduce the expression level of the huntingtin protein in glioma cells, for use thereof in sensitizing said cells to cancer treatment.

IPC Classes  ?

• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
• A61K 31/175 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine having the group , N—C(O)—N=N— or , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazonesThioanalogues thereof
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61N 5/00 - Radiation therapy
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to antisense oligonucleotides having the ability to reduce the expression level of the huntingtin protein in glioma cells, for use thereof in sensitizing said cells to cancer treatment.

IPC Classes  ?

• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61P 35/00 - Antineoplastic agents
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61N 5/00 - Radiation therapy
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
• A61K 31/175 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine having the group , N—C(O)—N=N— or , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazonesThioanalogues thereof
• A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol

Abstract

The disclosure relates to methods for treating tumors. In particular, the disclosure relates to a method of treating a tumor by ionizing radiations in a subject in need thereof, said method comprising the steps of: (i) injecting a first therapeutically effective amount of high-Z element containing nanoparticles as radiosensitizing agents in said subject in need thereof within a period between 2 and 7 days prior to the first irradiation of the tumor, (ii) injecting a second therapeutically effective amount of the same or different high-Z element containing nanoparticles within a period between 1 hour to 12 hours prior to the first irradiation of the tumor, and, (iii) irradiating the tumor of said subject with a therapeutically efficient dose of radiations; wherein said high-Z element containing nanoparticles are nanoparticles containing an element with an atomic Z number higher than 40 and said nanoparticles have a mean hydrodynamic diameter below 10 nm.

IPC Classes  ?

• A61K 51/06 - Macromolecular compounds
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
• A61K 49/12 - Macromolecular compounds
• A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
• A61P 35/00 - Antineoplastic agents

Abstract

Microvascular dysfunction remains a major contributor to the development of skin complications. The inventors assessed the impact of the local inhibition of soluble epoxide hydrolase (sEH), which metabolizes vasodilator and anti-inflammatory epoxyeicosanoids, on the diabetic skin microvascular dysfunction. The inventors have therefore developed some formulations of sEH inhibitors (GSK2256294 and t-AUCB) for topical administration. In particular, they show that an aqueous gel containing 400 mg/L t-AUCB dissolved in 50% dimethy lsulfo xide (DMSO) allowed a stable and continuous diffusion of t-AUCB from 2 hours after application on skin pig ears to over a period of 24 h. Compared to a control gel, the gel with t-AUCB did not significantly modify the basal skin blood flow but improved the altered hyperemic response of db/db mice 2 hours after application. The results show that the topical administration of a sEH inhibitor improves the skin microcirculatory function, representing a promising pharmacological approach to prevent the development of skin complications especially in diabetic patients.

IPC Classes  ?

• A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61P 17/00 - Drugs for dermatological disorders
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

A support for a biological species sample collected on a sampling device including a gripping rod and a capture element having a capture surface for receiving the sample. The capture element being assembled with the gripping rod in order to form a distal portion of the sampling device. The support has a flat main face delimited by at least one side and a recess opening on the side of the support in which the sampling device can be inserted. The recess has a groove formed on the main face of the support in order to receive the distal portion of the sampling device. The groove being configured to interact with the distal portion in order to securely hold it on or in the support.

IPC Classes  ?

• A61B 10/02 - Instruments for taking cell samples or for biopsy
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

In the present invention, inventors report the characterization of BCLA (Brain Cyst Load-associated Antigen), a protein exclusively expressed during the bradyzoite stage of the parasite. In cysts directly purified from the brain of mice, the protein is distributed within and at the surface of the cyst. ELISA antibody capture using a combination of serologically reactive BCLA peptides and a recombinantly expressed c-terminal domain (rBCLA) constitutes an efficient serological marker of latent infection with a high sensitivity that is clearly and exclusively correlated with the presence of cysts in the brain of mice. Antibodies directed against BCLA antigen have been detected in human patients with enriched titers in patients qualified as seropositive to Sag1 or tachyzoite related antigens. Further correlation in humans between anti-BCLA IgG synthesis and cysts is brought by significantly stronger recorded titers in pathological panels strongly related to the presence of cyst. Furthermore, newborn infants with a confirmed congenital toxoplasmosis display significantly higher anti-BCLA IgGs at birth when compared to their mother, suggesting a specific in-utero neosynthesis of such IgGs. Thus the invention relates to a new Toxoplasma gondii protein, hereafter referred as BCLA, a new serological marker whose expression is restricted to the latent form of Toxoplasmosis (bradyzoite/cyst). This specific protein and its antigenic fragments can be used to detect autoantibodies in the sera of patient for the diagnosis of the latent form of Toxoplasmosis. The invention also relates to derived antibodies, generated by BCLA immunisation that specifically binds this new protein.

IPC Classes  ?

• C07K 14/45 - Toxoplasma

Abstract

The disclosure relates to methods for treating tumors. In particular, the disclosure relates to a method of treating a tumor by ionizing radiations in a subject in need thereof, said method comprising the steps of: (i) injecting a first therapeutically effective amount of high-Z element containing nanoparticles as radiosensitizing agents in said subject in need thereof within a period between 2 and 7 days prior to the first irradiation of the tumor, (ii) injecting a second therapeutically effective amount of the same or different high-Z element containing nanoparticles within a period between 1 hour to 12 hours prior to the first irradiation of the tumor, and, (iii) irradiating the tumor of said subject with a therapeutically efficient dose of radiations; wherein said high-Z element containing nanoparticles are nanoparticles containing an element with an atomic Z number higher than 40 and said nanoparticles have a mean hydrodynamic diameter below 10 nm.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 35/00 - Antineoplastic agents
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

Abstract

The disclosure relates to methods for treating tumors. In particular, the disclosure relates to a method of treating a tumor by ionizing radiations in a subject in need thereof, said method comprising the steps of: (i) injecting a first therapeutically effective amount of high-Z element containing nanoparticles as radiosensitizing agents in said subject in need thereof within a period between (2) and (7) days prior to the first irradiation of the tumor, (ii) injecting a second therapeutically effective amount of the same or different high-Z element containing nanoparticles within a period between (1) hour to (12) hours prior to the first irradiation of the tumor, and, (iii) irradiating the tumor of said subject with a therapeutically efficient dose of radiations; wherein said high-Z element containing nanoparticles are nanoparticles containing an element with an atomic Z number higher than (40) and said nanoparticles have a mean hydrodynamic diameter below (10) nm.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 35/00 - Antineoplastic agents
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

Abstract

The disclosure relates to methods for treating tumors. In particular, the disclosure relates to a method of treating a tumor by ionizing radiations in a subject in need thereof, said method comprising the steps of: (i) injecting a first therapeutically effective amount of high-Z element containing nanoparticles as radiosensitizing agents in said subject in need thereof within a period between 2 and 7 days prior to the first irradiation of the tumor, (ii) injecting a second therapeutically effective amount of the same or different high-Z element containing nanoparticles within a period between 1 hour to 12 hours prior to the first irradiation of the tumor, and, (iii) irradiating the tumor of said subject with a therapeutically efficient dose of radiations; wherein said high-Z element containing nanoparticles are nanoparticles containing an element with an atomic Z number higher than 40 and said nanoparticles have a mean hydrodynamic diameter below 10 nm.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy
• A61P 35/00 - Antineoplastic agents

Abstract

ttttt-AUCB did not significantly modify the basal skin blood flow but improved the altered hyperemic response of db/db mice 2 hours after application. The results show that the topical administration of a sEH inhibitor improves the skin microcirculatory function, representing a promising pharmacological approach to prevent the development of skin complications especially in diabetic patients.

IPC Classes  ?

• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/415 - 1,2-Diazoles
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

The invention relates to a method for estimating the attentional resources invoked for execution of a primary task and/or attention sharing strategies developed by an individual, said method being implemented in a mobile terminal, being based on utilization of the dual-task paradigm, and comprising the following steps: Evaluation of first performance ratings of the individual during the execution of a primary task alone, Evaluation of second performance ratings of the individual during the execution of a secondary task alone, Evaluation of third performance ratings of the individual during the simultaneous execution of the primary and secondary tasks, Estimation of the attentional demand required for the execution of the primary task and/or of the effect (beneficial or negative) of a secondary task on the control mechanisms involved in the execution of the primary task and/or attention sharing strategies developed by an individual by comparing the first, second, and third performance ratings.

IPC Classes  ?

• G09B 19/00 - Teaching not covered by other main groups of this subclass
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• G09B 7/02 - Electrically-operated teaching apparatus or devices working with questions and answers of the type wherein the student is expected to construct an answer to the question which is presented or wherein the machine gives an answer to the question presented by the student
• G09B 7/00 - Electrically-operated teaching apparatus or devices working with questions and answers
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Mesothelin (MSLN) has been found to be overexpressed in several human malignancies: 100% of epithelial mesotheliomas, the majority of pancreatic and ovarian adenocarcinomas, more than 50 % of lung adenocarcinomas and 34 to 67 % of triple negative breast cancer (TNBC). The limited expression of mesothelin in normal human tissues and its overexpression in several aggressive human cancers make MSLN an attractive candidate for therapy. The objective of the inventors was to perform the nuclear imaging of TNBC xenografts with anti-MSLN single domain antibodies radiolabeled with 99mTc (99mTc-A1 and 99mTc-C6). They showed that 99mTc-A1 represent a good candidate for targeting mesothelin positive tumors. Accordingly, the present invention to an anti-mesothelin single domain antibody which is labelled with a radionuclide and its uses for imaging and/or treating cancer.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents

Abstract

A device for acclimatising at altitude comprising a breathing mask defining a confined air space when it is placed on the face of a user. The mask comprising a suction valve to let the surrounding air enter inside the confined space when breathing in; an expiration valve to let air exit with a determined resistance, so as to create an overpressurisation of air in the confined space, when breathing out; and a sensor to establish information about the pressure of the confined space behind. The acclimatisation device in addition comprises a unit for processing the pressure information configured to establish a breathing characteristic of the user and compare it to at least one target value, in view of recommending to them an adjustment of the breathing mode thereof. A method for functioning this device is also provided.

IPC Classes  ?

• A63B 23/18 - Exercising apparatus specially adapted for particular parts of the body for improving respiratory function
• A63B 71/06 - Indicating or scoring devices for games or players
• A63B 24/00 - Electric or electronic controls for exercising apparatus of groups
• A61M 16/06 - Respiratory or anaesthetic masks
• A61M 16/20 - Valves specially adapted to medical respiratory devices
• A63B 21/008 - Exercising apparatus for developing or strengthening the muscles or joints of the body by working against a counterforce, with or without measuring devices using hydraulic or pneumatic force-resisters
• A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
• A61M 16/08 - BellowsConnecting tubes

Abstract

The invention relates to a support (6) for a biological species sample collected on a sampling device comprising a gripping rod (2) and a capture element (3) having a capture surface (3a) for receiving the sample, the capture element being assembled with the gripping rod (2) in order to form a distal portion of the sampling device. The support (6) has a flat main face (6a) delimited by at least one side and a recess opening on the side of the support (6) in which the sampling device can be inserted. According to the invention, the recess consists of a groove (7) formed on the main face (6a) of the support (6) in order to receive the distal portion of the sampling device, the groove (7) being configured to interact with the distal portion in order to securely hold it on or in the support (6).

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers

Abstract

The invention relates to a method for estimating the attentional resources invoked for the execution of a primary task and/or attention sharing strategies developed by an individual, said method being implemented in a mobile terminal and being based on the utilization of the dual-task paradigm, noteworthy in that it comprises the following steps: - Evaluation (10) of first performance ratings of the individual during the execution of a primary task alone, - Evaluation (20) of second performance ratings of the individual during the execution of a secondary task alone, - Evaluation (30) of third performance ratings of the individual during the simultaneous execution of the primary and secondary tasks, - Estimation (40) of the attentional demand required for the execution of the primary task and/or of the effect (beneficial or negative) of a secondary task on the control mechanisms involved in the execution of the primary task and/or attention sharing strategies developed by an individual by comparing the first, second and third performance ratings evaluated during the previous steps.

IPC Classes  ?

• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G09B 7/00 - Electrically-operated teaching apparatus or devices working with questions and answers
• G09B 19/00 - Teaching not covered by other main groups of this subclass

Abstract

The invention relates to an altitude acclimatisation device (1) comprising a breathing mask (2) defining a confined air space when it is placed on the face of a user, the mask (2) comprising an inhalation valve (4a) for letting surrounding air into the confined space during inhalation; an exhalation valve for letting air out with a determined resistance in such a way as to create positive air pressure in the confined space during exhalation; and a sensor (5) for establishing pressure information about the rear confined space. The acclimatisation device (1) also comprises a unit for processing the pressure information, designed to establish a breathing characeristic of the user and to compare it with at least one target value, so as to be able to advise the user on adjustment of his or her breathing pattern. The invention also relates to a method for operating said device.

IPC Classes  ?

• A63B 23/18 - Exercising apparatus specially adapted for particular parts of the body for improving respiratory function
• A63B 24/00 - Electric or electronic controls for exercising apparatus of groups
• A63B 71/06 - Indicating or scoring devices for games or players
• A63B 21/008 - Exercising apparatus for developing or strengthening the muscles or joints of the body by working against a counterforce, with or without measuring devices using hydraulic or pneumatic force-resisters
• A61M 16/08 - BellowsConnecting tubes

Abstract

The invention relates to an X-ray imaging device including a rotary collimator having a region (22) which is opaque to X-rays, a first slot (24) and a second slot (26), which are transparent to X-rays and extend in two different directions, passing through said opaque region, the collimator making it possible to determine the position of an element provided with X-ray sensors in an imaging system.

IPC Classes  ?

• G01T 7/00 - Details of radiation-measuring instruments
• G01N 23/04 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by transmitting the radiation through the material and forming images of the material
• A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
• G01T 1/164 - Scintigraphy

Abstract

The present invention relates to methods for amplifying and sequencing the full-length genome of a hepatitis C vims. The present invention also relates to primers and kits for amplifying and sequencing the full-length genome of a hepatitis C virus.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

The present invention relates to methods for amplifying and sequencing the full-length genome of a hepatitis C virus. The present invention also relates to primers and kits for amplifying and sequencing the full-length genome of a hepatitis C virus.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The invention relates to a method for determining the degree of sensitivity of a strain of fungus to an antifungal agent.

IPC Classes  ?

• C12Q 1/18 - Testing for antimicrobial activity of a material

Abstract

The invention relates to a method for determining the degree of sensitivity of a strain of fungus to an antifungal agent.

IPC Classes  ?

• C12Q 1/18 - Testing for antimicrobial activity of a material

Abstract

The present invention relates to a method for dynamically determining the structural profile of a fibrin clot, reflecting the stability thereof in a biological sample of a patient, said method comprising the following steps: a) mixing the undiluted biological sample with tissue factor or a mixture of tissue factor and tissue plasminogen activator; b) incubating the mixture obtained in step a), then adding calcium ions to the mixture obtained, in order to initiate the formation of a fibrin clot; c) measuring the turbidity or the optical density of the clot being formed in step b), at at least two wavelengths of between 450 nm and 850 nm, and for a time of between 1 and 35 minutes; d) determining the structural profile of the analysed clot, expressed as a number of protofibrils, density and radius in c) by means of the formula τ.λ5 = A [Fg].(λ2 - B), wherein τ is the turbidity of the clot at a given wavelength λ, [Fg] is the initial weight concentration of fibrinogen, and A and B are coefficients which are proportional, respectively, to the density and the radius of the fibres that make up the clot; and e) comparing the obtained profile with a control. The method preferably includes a step f) that makes it possible to predict the risk of bleeding, thrombosis or rethrombosis and to select the anticoagulant that is best suited to the clinical situation of a patient.

IPC Classes  ?

• G01N 33/49 - Physical analysis of biological material of liquid biological material blood

Abstract

A method and device for detecting a worsening of the cardio-respiratory condition of a patient treated using a respiratory assistance device comprising means for collecting and processing parameters indicative: - of a first parameter indicative of the breathing rate in a first observation window; - of a second parameter indicative of the percentage of cycles initiated by the patient during a second observation window; - of a third parameter indicative of the duration of use of the apparatus during a third observation window. The method is characterized in that it involves detecting a significant variation in one of said parameters over at least two consecutive or non-consecutive days during a consecutive period of n days, where n is strictly greater than 3 and preferably greater than or equal to 5; and, in response to said detection, generating an alert intended for said patient or for a practitioner in order to inform same of a significant risk of worsening of the cardio-respiratory condition of the patient.

IPC Classes  ?

• A61B 5/08 - Measuring devices for evaluating the respiratory organs
• A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The invention relates to a method for the in vitro detection of strains of Legionella pneumophila that are resistant to antibiotics, especially fluoroquinolones. The invention also relates to nucleotide probes and to a kit of reagents allowing the detection of bacterial strains of Legionella pneumophila that are resistant to antibiotics, especially of the fluoroquinolone type.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to pyrrolic derivatives I, processes for their preparation, and their use as new antibacterial drugs.

IPC Classes  ?

• C07D 207/333 - Radicals substituted by oxygen or sulfur atoms
• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61P 31/04 - Antibacterial agents

Abstract

The present invention relates to a method for dosing the control capacity of plasma serpin (SERine Protease INhibitor) C1 inhibitor (C1Inh) on the basis of a patient blood sample. The invention also relates to a kit specially designed for said dosing.

IPC Classes  ?

• C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase

Abstract

The present invention relates to nanobodies specifically directed against VCAM-1 and to the use thereof in medical imaging and in diagnostic, prognostic and treatment methods.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

The present patent application relates to a method for diagnosing angioedema with a gain-of-function mutation of kinin formation, and for determining the amount of BK or des-Arg9-BK antagonist required for halting the effects of angioedema, from a plasma sample of a patient. The invention also relates to a kit for said determination.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a method for predicting and/or diagnosing vascular alterations associated with a disorder in a patient, comprising a step of detecting or quantifying the presence of anti-VE-cadherin autoantibodies in a biological sample obtained from said patient as well as a kit suitable for carrying out such method.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease

Abstract

The invention relates to a method for the in vitro diagnosis of a brain tumour belonging to the group consisting of two types of tumours - ODG and GBM - and the identification of the type of tumour, comprising the measurement of the expression levels of at least one first and one second miRNA respectively belonging to two different miRNA groups, in a sample from a patient suspected of having one of said brain tumours.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The invention relates to a method for the in vitro diagnosis of a brain tumour belonging to the group consisting of two types of tumours - ODG and GBM - and the identification of the type of tumour, comprising the measurement of at least two ratios of the expression levels of miRNA pairs extracted from a biological sample from a patient suspected of having one of said brain tumours.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates to a device for controlling a blood flow produced in a hemorrhagic area (4) of biological tissue (8), including a flexible plate (2) that is arranged so as to be placed opposite said area (4) and includes: a substantially sealed peripheral bearing means (3) capable of being applied onto the biological tissue (8) while surrounding the hemorrhagic area; a bottom wall (5) that defines, together with the bearing means (3), a hollow space (6) opposite the area (4); a connection means (14, 15) arranged so as to connect the hollow space (6), outside the flexible plate (2), to an outer suction source so as to create, within the hollow space (6), a vacuum for suctioning and tightly applying the surface (7) of the tissue (8) against the peripheral bearing means (3); and a hollow contact pad (11) which is placed between the area (4) and the bottom wall (5), which has a recess in the center thereof on the area (4) side and along an axis (10) substantially perpendicular to the bottom wall, and which is arranged so as to be in contact with the area (4) when the vacuum is created in the space (6).

IPC Classes  ?

• A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
• A61M 27/00 - Drainage appliances for wounds, or the like
• A61B 17/30 - Surgical pincettes, i.e. surgical tweezers

Abstract

The present invention relates to a hemostatic device (23) for controlling a blood flow occurring in a hemorrhagic zone (4) located in a hollow component, comprising: - a flexible plate (26) equipped with two opposing faces (27, 28), substantially parallel, said plate comprising an empty internal volume (29) between its two faces, and - connection means (30) linked for connecting the internal volume (29) to suction means external to said device, so as to create a depression in this internal volume (29), said connection means typically comprising a connecting tube (31), each of the faces (27, 28) being equipped with holes (32) that communicate, via these faces (27, 28), the internal volume (29) and the exterior of the plate such that when said depression is created in the internal volume, the suction is applied simultaneously to two opposite walls of the hollow component so as to keep them close together.

IPC Classes  ?

• A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
• A61M 27/00 - Drainage appliances for wounds, or the like

Abstract

The present invention relates to a device for controlling a blood flow produced in a hemorrhagic area (4) of biological tissue (8), including a flexible plate (2) that is arranged so as to be placed opposite said area (4) and includes: a substantially sealed peripheral bearing means (3) capable of being applied onto the biological tissue (8) while surrounding the hemorrhagic area; a bottom wall (5) that defines, together with the bearing means (3), a hollow space (6) opposite the area (4); a connection means (14, 15) arranged so as to connect the hollow space (6), outside the flexible plate (2), to an outer suction source so as to create, within the hollow space (6), a vacuum for suctioning and tightly applying the surface (7) of the tissue (8) against the peripheral bearing means (3); and a hollow contact pad (11) which is placed between the area (4) and the bottom wall (5), which has a recess in the center thereof on the area (4) side and along an axis (10) substantially perpendicular to the bottom wall, and which is arranged so as to be in contact with the area (4) when the vacuum is created in the space (6).

IPC Classes  ?

• A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
• A61M 27/00 - Drainage appliances for wounds, or the like
• A61B 17/30 - Surgical pincettes, i.e. surgical tweezers

Abstract

The invention relates to a device for transiently contacting at least one unit for capturing biological targets with a body fluid containing them, a method for recovering the captured targets for analysis, and a system for contacting and recovering a capture substrate included in said unit. The invention relates to samples obtained in particular in vivo from body fluids of the human body, e.g. circulating body fluids, said fluids possibly containing, as targets, proteins, oligonucleotides such as RNA or DNA, antibodies, enzymes or cells. A contacting device (1) according to the invention comprises: - a sampling tip (2) having a contacting end intended to be introduced into a medium containing said fluid, and - the or each capturing unit which is bound to said end and which comprises a capture substrate (3) defining a target capturing surface covered with at least one biocompatible and porous crosslinked polymer layer (4) designed to retain the or each capture substrate and only to allow biological particles including targets smaller than a limiting size to pass through, in such a way that the or each capture substrate is recoverable after said contacting by dissolution of the or each layer.

IPC Classes  ?

• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements

Abstract

The present invention relates to a surgical instrument (1) for sampling molecules from an organ to which access is possible directly or via a surgical approach, including: a device (5) for capturing said molecules, a stylus (4) supporting said capture device (5) and which is capable of penetrating the organ, and a guide (3) for inserting the stylus (4) into the body up to the organ, characterized in that the distal end of the guide (3) is provided with a damping block (6) intended to bear against the organ.

IPC Classes  ?

• A61B 10/02 - Instruments for taking cell samples or for biopsy
• A61B 17/00 - Surgical instruments, devices or methods
• A61B 17/34 - TrocarsPuncturing needles
• A61B 19/00 - Instruments, implements or accessories for surgery or diagnosis not covered by any of the groups A61B 1/00-A61B 18/00, e.g. for stereotaxis, sterile operation, luxation treatment, wound edge protectors(protective face masks A41D 13/11; surgeons' or patients' gowns or dresses A41D 13/12; devices for carrying-off, for treatment of, or for carrying-over, body liquids A61M 1/00)

Abstract

The invention relates to a device for in vivo dosimetry, consisting of: a miniature probe (1) comprising at least (i) a radioluminescent material (3) which emits a luminescence signal having an intensity that varies according to the high-energy radiation irradiating the material (ii) and an optical fibre (4) which receives the radioluminescence signal and transmits same to a luminescence detection system (14); and a luminescence detection system. The invention is characterised in that the radioluminescent material is gallium nitride (GaN), emitting a luminescence signal in at least one narrowband (BE), and in that the luminescence detection system (14) includes an optical device (18) that can be used to select the gallium nitride emission narrowband.

IPC Classes  ?

• G01T 1/161 - Applications in the field of nuclear medicine, e.g. in vivo counting
• G01T 1/20 - Measuring radiation intensity with scintillation detectors